Abeona Therapeutics Inc
Research Abeona Therapeutics Inc (ABEO) on Bullrun: market cap USD 282.70M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABEO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 282.70M
- Financial periodQ2 2026
- RevenueUSD 11.38M
- Net income-USD 20.19M
- Free cash flow-USD 17.98M
- Gross margin63.3%
Valuation Snapshot
latest market cap is USD 282.70M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 5.82M | -USD 71.18M | -USD 84.30M | 73.7% | 1.01 | USD 78.44M | USD 20.04M | USD 159.22M |
| FY2024 | USD 0 | USD 63.73M | -USD 58.46M | n/a | -1.55 | USD 23.36M | USD 18.96M | USD 44.03M |
| FY2023 | USD 3.50M | USD 54.19M | -USD 37.34M | 54.1% | -2.53 | USD 14.47M | USD 5.40M | USD 14.83M |
| FY2022 | USD 1.41M | -USD 39.70M | -USD 43.61M | 68.2% | -5.53 | USD 14.22M | USD 7.63M | USD 26.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 282.70M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 290.08M | 5.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 254.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 124.11M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 52.90M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 50.05M | n/a | n/a | n/a |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Abeona Therapeutics Inc's market cap?
Abeona Therapeutics Inc's market capitalization is USD 282.70M.
What does Abeona Therapeutics Inc do?
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.